The state of Massachusetts currently has 161 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Lahey Hospital and Medical Center, Burlington, Massachusetts +3 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
NCT05511844
Recruiting
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Register for Updates
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT03285412
Recruiting
This research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Breast Cancer
Register for Updates
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT04039230
Recruiting
This research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT02632448
Recruiting
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Register for Updates
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492
Recruiting
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question[s] it aims to answer are: the recommended dose for Phase 2 to evaluate the safety and tolerability of the combination therapy to determine the pharmacokinetics of TNG260 to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer, Pancreatic Cancer, Cervical Cancer, Breast Cancer, Carcinoma of Unknown Primary
Register for Updates
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
NCT06001762
Recruiting
In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage high-risk hormone receptor positive breast cancer. The names of the study drugs involved in this study are: Abemaciclib (CDK4 and CDK6 inhibitor) Tamoxifen (Selective estrogen receptor modulator) Anastrozole/Letrozole (Non-steroidal aromatase inhibitors) Exemestane (steroidal... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +6 locations
Conditions: Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
Register for Updates
Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
NCT03861975
Recruiting
This research will compare the absolute volumes of the upper extremity using both the LymphaTech Scanner and Perometer in a cohort of patients with a history of invasive or in-situ carcinoma of the breast.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512
Recruiting
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
NCT04593277
Recruiting
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. By improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
Register for Updates
A Study of XMT-1660 in Participants With Solid Tumors
NCT05377996
Recruiting
A Study of XMT-1660 in Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +1 locations
Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Register for Updates
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT02290834
Recruiting
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
Gender:
Female
Ages:
60 years and above
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Impaired Cognition, Chemo-brain, Breast Cancer
Register for Updates